Quick Answer
Amneal Pharmaceuticals, Inc. reported Operating Income of $394.10 million for fiscal year 2025.
Amneal Pharmaceuticals, Inc. Operating Income — Annual History
| Fiscal Year | Operating Income | YoY Change |
|---|---|---|
| 2025 | $394.10M | +58.1% |
| 2024 | $249.33M | +22.0% |
| 2023 | $204.37M | +315.3% |
| 2022 | -$94.93M | -162.2% |
| 2021 | $152.72M | +67.5% |
| 2020 | $91.16M | +136.7% |
| 2019 | -$248.68M | -1164.1% |
| 2018 | -$19.67M | -108.0% |
| 2017 | $245.10M | -14.0% |
| 2016 | $284.88M | — |
Quarterly Operating Income
| Quarter Ending | Operating Income | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $70.34M | -20.8% | -36.8% |
| June 30, 2025 | $111.37M | +16.7% | +11.0% |
| March 31, 2025 | $100.35M | +1033.8% | +13.0% |
| September 30, 2024 | $88.81M | +17.4% | -7.0% |
| June 30, 2024 | $95.47M | +19.2% | +988.4% |
| March 31, 2024 | -$10.75M | -131.2% | -114.2% |
| September 30, 2023 | $75.65M | +70.6% | -5.5% |
| June 30, 2023 | $80.08M | +140.3% | +132.5% |
- Amneal Pharmaceuticals, Inc. showed an increase of +58.1% in Operating Income compared to the prior fiscal year.
- Over the 2016–2025 period, Amneal Pharmaceuticals, Inc.’s operating income has grown by 38.3% (from $284.88 million to $394.10 million).
- The most recent figure is from Amneal Pharmaceuticals, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on February 27, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: